THIS WEEK'S FEATURE
BriaCell Therapeutics (TSXV:BCT; OTCQB:BCTXF) has reported impressive early safety and efficacy data with its lead immunotherapies for the treatment of advanced breast cancer.
MediXall Group (OTCQB:MDXL) has launched a new generation healthcare marketplace platform to address self-pay and high deductible consumers’ growing need for greater healthcare cost transparency and access to competitive pricing information.
Ceapro (TSXV:CZO) is transitioning to a new business model - from a contract manufacturer to a biopharmaceutical company - to pursue multiple growth opportunities in nutraceuticals and pharmaceuticals.
Closely-held Leviticus Cardio of Israel is developing a wireless system capable of providing day-to-day power needs for implanted ventricular assist devices (VADs), eliminating the complications that congestive heart failure (CHF) patients face with existing VADs.
As managing director, life sciences specialty services at BDO, the global professional services firm, Susan Linna has more than 25 years of drug, vaccine and biologic development experience, 13 of which were at a Fortune 100 pharmaceutical company, and 13 years in biotechnology.